Health Care • Biotechnology: Pharmaceutical Preparations
$5.88 ▲ +0.01
(+0.17%)
MKT CAP: $73.9M • VOL: 24.1K
52W L $4 52W H $12
LFVN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-06-30 | FY 2024
FILED 2024-06-30 | FY 2023
FILED 2023-06-30 |
|---|---|---|---|
| Revenue (Total Sales) | $228.5M | $200.2M | $213.4M |
| YoY Revenue Growth % | +14.2% | -6.2% | — |
| Gross Profit | $183.7M | $158.7M | — |
| Gross Margin % | 80.4% | 79.3% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $12.2M | $4.3M | $4.3M |
| Operating Margin % | 5.3% | 2.2% | 2.0% |
| Net Income (GAAP) | $9.8M | $2.9M | $2.5M |
| EBITDA (Normalized) | $13.3M | $6.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $11.9M | $12.2M | $6.8M |
| Capital Expenditures (CapEx) | $1.4M | $2.2M | — |
| Free Cash Flow (FCF) | $10.5M | $10.0M | $6.8M |
| FCF Margin % | 4.6% | 5.0% | 3.2% |
| Return on Invested Capital (ROIC %) | 29.2% | 11.4% | — |
| Cash & Short-Term Equivalents | — | — | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $33.0M | $29.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR LFVN.